Bristol-Myers Squibb Files Proxy Materials

TL;DR

BMS filed proxy docs, no fee. Standard corporate stuff.

AI Summary

Bristol-Myers Squibb Company filed a Definitive Additional Materials proxy statement on April 22, 2024. This filing is related to the company's proxy materials and does not involve a fee, as indicated by the "No fee required" checkbox. The filing is made under the Securities Exchange Act of 1934.

Why It Matters

This filing is a routine proxy statement update, indicating the company is proceeding with standard corporate governance procedures, such as shareholder meetings and voting processes.

Risk Assessment

Risk Level: low — This is a routine administrative filing related to proxy statements and does not contain new financial information or strategic decisions that would typically impact risk.

Key Players & Entities

• Bristol-Myers Squibb Company (company) — Registrant
• 0001140361-24-020908 (filing_id) — Accession Number
• 20240422 (date) — Filing Date
• 1934 Act (regulation) — SEC Act

FAQ

Key Financial Figures

• $45.0B — w drugs per year**1 2023 Total Revenues $45.0B GAAP Full Year 2023 EPS $3.86* GAAP Ful
• $3.86 — Revenues $45.0B GAAP Full Year 2023 EPS $3.86* GAAP Full Year * GAAP diluted EPS incl
• $0.28 — d IPRD charges and licensing income of ($0.28) in 2023. Acquired IPRD refers to certa
• $1 billion — ortune 100 companies that have invested $1 billion with diverse-owned suppliers 3 4 Deli
• $34.3B — s in 2023 Strong Commercial Performance $34.3B $3.6B $7.1B In-Line Products* New Produ
• $3.6B — 23 Strong Commercial Performance $34.3B $3.6B $7.1B In-Line Products* New Product Por
• $7.1B — ong Commercial Performance $34.3B $3.6B $7.1B In-Line Products* New Product Portfolio
• $33.3B — sales compared to net sales compared to $33.3B in 2022 $2.0B in 2022 $10.8B in 2022 $3
• $2.0B — to net sales compared to $33.3B in 2022 $2.0B in 2022 $10.8B in 2022 $3.86 $7.51 GAAP
• $10.8B — ompared to $33.3B in 2022 $2.0B in 2022 $10.8B in 2022 $3.86 $7.51 GAAP diluted EPS No
• $7.51 — 2022 $2.0B in 2022 $10.8B in 2022 $3.86 $7.51 GAAP diluted EPS Non-GAAP diluted EPS +
• $13.9B — 22 Balanced Capital Allocation Strategy $13.9B 5.6% $5.2B in cash flow from quarterly
• $5.2B — Capital Allocation Strategy $13.9B 5.6% $5.2B in cash flow from quarterly dividend in
• $1B — ican (U.S.) Latino (U.S.) (Global) 58% >$1B Clinical trial sites in Global spend wi
• $118.3M — HCARE BMS has distributed approximately $118.3M in grant funding to support programs an

Filing Documents

• ef20027324_defa14a.htm (DEFA14A) — 54KB
• ef20027324_defa14aslide1.jpg (GRAPHIC) — 132KB
• ef20027324_defa14aslide2.jpg (GRAPHIC) — 102KB
• ef20027324_defa14aslide3.jpg (GRAPHIC) — 186KB
• ef20027324_defa14aslide4.jpg (GRAPHIC) — 178KB
• ef20027324_defa14aslide5.jpg (GRAPHIC) — 181KB
• ef20027324_defa14aslide6.jpg (GRAPHIC) — 133KB
• ef20027324_defa14aslide7.jpg (GRAPHIC) — 209KB
• ef20027324_defa14aslide8.jpg (GRAPHIC) — 151KB
• ef20027324_defa14aslide9.jpg (GRAPHIC) — 157KB
• ef20027324_defa14aslide10.jpg (GRAPHIC) — 195KB
• ef20027324_defa14aslide11.jpg (GRAPHIC) — 141KB
• ef20027324_defa14aslide12.jpg (GRAPHIC) — 242KB
• ef20027324_defa14aslide13.jpg (GRAPHIC) — 327KB
• ef20027324_defa14aslide14.jpg (GRAPHIC) — 336KB
• ef20027324_defa14aslide15.jpg (GRAPHIC) — 33KB
• 0001140361-24-020908.txt ( ) — 3779KB

Forward Looking Statements and Non-GAAP Financial Information 14 This

Forward Looking Statements and Non-GAAP Financial Information 14 This presentation (as well as the oral statements made with respect to information contained in this presentation) contains statements about Bristol-Myers Squibb Company's (the "Company") future financial results, plans, business development strategy, anticipated clinical trials, results and regulatory approvals that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Actual results may differ materially from those expressed in, or implied by, these statements as a result of various factors, including, but not limited to, (i) new laws and regulations, (ii) our ability to obtain, protect and maintain market exclusivity rights and enforce patents and other intellectual property rights, (iii) our ability to achieve expected clinical, regulatory and contractual milestones on expected timelines or at all, (iv) difficulties or delays in the development and commercialization of new products, (v) difficulties or delays in our clinical trials and the manufacturing, distribution and sale of our products, (vi) adverse outcomes in legal or regulatory proceedings, (vii) risks relating to acquisitions, divestitures, alliances, joint ventures and other portfolio actions and (viii) political and financial instability, including changes in general economic conditions. These and other important factors are discussed in the Company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q and current reports on Form 8-K. These documents are available on the U.S. Securities and Exchange Commission's website, on the Company's website or from Bristol-Myers Squibb Investor Relations. No forward-looking statements can be guaranteed. In addition, any forward-looking statements and clinical data included here

View Full Filing

View this DEFA14A filing on SEC EDGAR